Challenges in the clinical development of non-D2 compounds for schizophrenia

References

• McCutcheon RA, Krystal JH, Howes OD. Dopamine and glutamate in schizophrenia: biology, symptoms and treatment. World Psychiatry. 2020;19(1):15–33.
   PubMed Web of Science ®Google Scholar
• Kraguljac NV, McDonald WM, Widge AS, et al. Neuroimaging biomarkers in schizophrenia. Am J Psychiatry. 2021;178(6):509–521.
   PubMed Web of Science ®Google Scholar
• Leucht S, Leucht C, Huhn M, et al. Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, bayesian meta-analysis, and meta-regression of efficacy predictors. Am J Psychiatry. 2017;174(10):927–942.
   PubMed Web of Science ®Google Scholar
• Higashi K, Medic G, Littlewood KJ, et al. Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review. Ther Adv Psychopharmacol. 2013;3(4):200–218.
   PubMedGoogle Scholar
• Taub S, Krivoy A, Whiskey E, et al. New approaches to antipsychotic medication adherence - safety, tolerability and acceptability. Expert Opin Drug Saf. 2022;21(4):517–524.
   PubMed Web of Science ®Google Scholar
• Kapur S, Zipursky R, Jones C, et al. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry. 2000;157(4):514–520.
   PubMed Web of Science ®Google Scholar
• Kapur S, Roy P, Daskalakis J, et al. Increased dopamine d(2) receptor occupancy and elevated prolactin level associated with addition of haloperidol to clozapine. Am J Psychiatry. 2001;158(2):311–314.
   PubMed Web of Science ®Google Scholar
• Miller DD, Caroff SN, Davis SM, et al. Extrapyramidal side-effects of antipsychotics in a randomised trial. Br J Psychiatry. 2008;193(4):279–288.
   PubMed Web of Science ®Google Scholar
• Caroff SN, Hurford I, Lybrand J, et al. Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial. Neurol Clin. 2011;29(1):127–148, viii.
   PubMed Web of Science ®Google Scholar
• Carbon M, Hsieh CH, Kane JM, et al. Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis. J Clin Psychiatry. 2017;78(3):e264–e278.
   PubMed Web of Science ®Google Scholar
• Peuskens J, Pani L, Detraux J, et al. The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review. CNS Drugs. 2014;28(5):421–453.
   PubMed Web of Science ®Google Scholar
• Kaar SJ, Natesan S, McCutcheon R, et al. Antipsychotics: mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology. Neuropharmacology. 2020;172:107704.
   PubMed Web of Science ®Google Scholar
• Correll CU, Abi-Dargham A, Howes O. Emerging treatments in schizophrenia. J Clin Psychiatry. 2022;83(1):SU21204IP1.
   PubMed Web of Science ®Google Scholar
• Dedic N, Dworak H, Zeni C, et al. Therapeutic potential of TAAR1 agonists in schizophrenia: evidence from preclinical models and clinical studies. Int J Mol Sci. 2021;22(24):13185.
   PubMed Web of Science ®Google Scholar
• Spark DL, Fornito A, Langmead CJ, et al. Beyond antipsychotics: a twenty-first century update for preclinical development of schizophrenia therapeutics. Transl Psychiatry. 2022;12(1):147.
   PubMed Web of Science ®Google Scholar
• Köster LS, Carbon M, Correll CU. Emerging drugs for schizophrenia: an update. Expert Opin Emerg Drugs. 2014;19(4):511–531.
   PubMed Web of Science ®Google Scholar
• Wong CH, Siah KW, Lo AW. Estimation of clinical trial success rates and related parameters. Biostatistics. 2019;20(2):273–286.
   PubMed Web of Science ®Google Scholar
• Dowden H, Munro J. Trends in clinical success rates and therapeutic focus. Nat Rev Drug Discov. 2019;18(7):495–496.
   PubMed Web of Science ®Google Scholar
• Zhu T. Challenges of psychiatry drug development and the role of human pharmacology models in early development. Front Psychiatry. 2020;11:562660.
   PubMed Web of Science ®Google Scholar
• Díaz-Mataix L, Scorza MC, Bortolozzi A, et al. Involvement of 5-HT1A receptors in prefrontal cortex in the modulation of dopaminergic activity: role in atypical antipsychotic action. J Neurosci. 2005;25(47):10831–10843.
   PubMed Web of Science ®Google Scholar
• Pehek EA, Nocjar C, Roth BL, et al. Evidence for the preferential involvement of 5-HT2A serotonin receptors in stress- and drug-induced dopamine release in the rat medial prefrontal cortex. Neuropsychopharmacology. 2006;31(2):265–277.
   PubMed Web of Science ®Google Scholar
• Zagórska A, Bucki A, Partyka A, et al. Design, synthesis, and behavioral evaluation of dual-acting compounds as phosphodiesterase type 10A (PDE10A) inhibitors and serotonin ligands targeting neuropsychiatric symptoms in dementia. Eur J Med Chem. 2022;233:114218.
   PubMed Web of Science ®Google Scholar
• Gupta I, Young AMJ. Metabotropic glutamate receptor modulation of dopamine release in the nucleus accumbens shell is unaffected by phencyclidine pretreatment: in vitro assessment using fast-scan cyclic voltammetry rat brain slices. Brain Res. 2018;1687:155–161.
   PubMed Web of Science ®Google Scholar
• Dedic N, Jones PG, Hopkins SC, et al. SEP-363856, a novel psychotropic agent with a unique, Non-D2 receptor mechanism of action. J Pharmacol Exp Ther. 2019;371(1):1–14.
   PubMed Web of Science ®Google Scholar
• Gribkoff VK, Kaczmarek LK. The need for new approaches in CNS drug discovery: why drugs have failed, and what can be done to improve outcomes. Neuropharmacology. 2017;120:11–19.
   PubMed Web of Science ®Google Scholar
• Scannell JW, Bosley J, Hickman JA, et al. Predictive validity in drug discovery: what it is, why it matters and how to improve it. Nat Rev Drug Discov. 2022. DOI:10.1038/s41573-022-00552-x
   PubMed Web of Science ®Google Scholar
• Vincent F, Nueda A, Lee J, et al. Phenotypic drug discovery: recent successes, lessons learned and new directions. Nat Rev Drug Discov. 2022. DOI:10.1038/s41573-022-00472-w
   Web of Science ®Google Scholar
• Kemp AS, Schooler NR, Kalali AH, et al. What is causing the reduced drug-placebo difference in recent schizophrenia clinical trials and what can be done about it? Schizophr Bull. 2010;36(3):504–509.
   PubMed Web of Science ®Google Scholar
• Rutherford BR, Pott E, Tandler JM, et al. Placebo response in antipsychotic clinical trials: a meta-analysis. JAMA Psychiatry. 2014;71(12):1409–1421.
   PubMed Web of Science ®Google Scholar
• Hopkins SC, Ogirala A, Loebel A, et al. Transformed PANSS factors intended to reduce pseudospecificity among symptom domains and enhance understanding of symptom change in antipsychotic-treated patients with schizophrenia. Schizophr Bull. 2018;44(3):593–602.
   PubMed Web of Science ®Google Scholar
• Correll CU, Schooler NR. Negative symptoms in schizophrenia: a review and clinical guide for recognition, assessment, and treatment. Neuropsychiatr Dis Treat. 2020;16:519–534.
   PubMed Web of Science ®Google Scholar
• Hopkins SC, Tomioka S, Ogirala A, et al. Assessment of negative symptoms in clinical trials of acute schizophrenia: test of a novel enrichment strategy. Schizophr Bull Open. 2022;3:sgac027.
   Google Scholar
• Juneja A, Gupta J, Yadav N, et al. An overview of primary registries of WHO's international clinical trial registry platform. Ayu. 2019;40(3):141–146.
   PubMedGoogle Scholar